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Experimental allergic encephalomyelitis (EAE)' is an autoimmune inflammatory
demyelinating disease in the central nervous system (CNS) of animals immunized
with myelin basicprotein (MBP). The disease isdirectly mediated by Thelper cells
that recognize MBP in the context ofclass II antigens ofthe MHC (1-3). In nude
mice, a single clone ofadoptively transferred MBP-reactive T helper cells can cause
EAE (4), suggesting that these are the only T cells required for disease induction.
Asa prototypic model ofT helper cell-mediated autoimmune disease, observations
in EAE could likely be applicable to other T helper cell-mediated diseases such as
murine lupus (5), thyroiditis (6), collagen arthritis (7), and adjuvant arthritis (8),
as well as human autoimmune diseases.
The MBP epitope is determined in part by the MHC. Using proteolytic peptide
fragments of MBP, SJL/J (H-2s) and BIO.T(6R) (H-2q) mice were found to develop
EAE to the COOH-terminal peptide of MBP, whereas PL/J (H-2u) and A/J (H-
2k) mice developed EAE to the NH2-terminal peptide of MBP (9). Recently, by
using synthetic peptides that overcomethedifficulties ofobtainingpureuncontami-
nated proteolytic peptides, a single T cell encephalitogenic epitope for PL/J mice
has been identified. This epitope consists ofthe first nine NH2-terminal amino acid
residues of MBP which must be acetylated at the a amino group to induce disease
(10). Similar fine mapping ofthe encephalitogenic T cell epitope(s) for SJL/J mice
has not been done, in part because ofthe large size ofthe COOH-terminal peptic
fragment of MBP (residues 89-169 of rat MBP, reference 9).
MouseMBP consists offourmajorforms due to differential RNA splicing ofexons
II and VI (11), resulting in molecular masses of 21, 18.5, 17.5, and 14 kD, in the
relative amounts of1:10:3.5:35. SinceEAEcan also beinducedwith the small form
ofrat MBP (14 kD), which has exons II and VI ofthe MBP gene deleted (12), the
COOH-terminalencephalitogenic determinantforSJL/J mice mustbepresent within
a segment ofonly42 amino acid residues. Consistent withthisnotion is theobserva-
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J. Exp. Mm. ® The Rockefeller University Press " 0022-1007/88/07/0213/15 $2 .00
￿
213
Volume 168 July 1988 213-227214 ENCEPHALITOGENIC T CELL EPITOPES IN SJL/J MICE
tion that this peptide sequence is identical among the MBPs of several mammalian
species, including mouse, rat, bovine, guinea pig, and porcine, all of which can in-
duce EAE in SJL/mice (13, 14).
To identify the SJL/J encephalitogenic T cell epitope(s), overlapping peptides to
the COOH-terminal region ofthe small form of mouse MBP were synthesized. Two
overlapping peptides encompassing an 18-amino acid region were found to elicit
EAE in SJL/J mice. The finding of a single peptide region of MBP that is respon-
sible for encephalitogenic T cell epitopes in SJL/J mice is analogous to that of the
PL/J mice and has implications for the development ofspecific therapy for T cell-medi-
ated autoimmune diseases.
Materials and Methods
Mice.
￿
SJL/J and PL/J mice (6-10 wk old) were purchased from TheJackson Laboratory,
Bar Harbor, ME. (SJL/J x PL/J)Fl mice were bred at the Caltech animal facility.
Peptides.
￿
Peptides were synthesized on a Peptide Synthesizer (model 430A; Applied Bio-
systems Inc., Foster City, CA) by using a stepwise solid-phase chemistry protocol and ma-
chine program developed at Caltech (15). The crude peptide product was purified by semi-
preparative HPLC on a C8, 10 mm LD. x 10 cm Brownlee column; 60 m linear gradient
100% A to 100% B; A: 0.1% TFA/Hz0; B: 0.1°Jo TFA/60% CH3CN/40%/Hz0; flow rate
0.7 ml/m.
Myelin BasicProtein.
￿
MBP was prepared from frozen brains (Pel-Freeze Biologicals, Rogers,
AR) as previously described (16).
Immunization.
￿
MBP or peptides were emulsified with an equal volume ofCFA supplemented
with 4 mg/ml Mycobacterium tuberculosis H37Ra (Difco Laboratories Inc., Detroit, MI). Mice
were immunized subcutaneously with 0.05 ml at two sites. At 24 and 72 h after immuniza-
tion, mice were given an intravenous injection of 6 x 109 washed, killed Bordetella pertussis
in saline (gift from Dr. Dale E. McFarlin, National Institutes of Health, Bethesda, MD).
Disease Severity.
￿
Clinical EAE was graded on a scaleof 1 to 5 usingpreviously established
standard criteria (1): grade 1, flaccid tail; grade 2, moderate hind or front leg weakness; grade
3, severe hind or front leg weakness; grade 4, complete paralysis of limb(s); grade 5, death.
T Cell Lines, Clones, and Hybridomas.
￿
Draining lymph node cells (LNC) were harvested
10 d after subcutaneous immunization with an emulsion of 200 wg rat MBP or 20 nmol of
peptide and an equal volume of CFA. 3 x 106 cells and 20 fig of rat MBP in a total volume
of 1 ml were incubated for 4 d in Ventrex HL-1 medium (Fisher Scientific Co., Pittsburgh,
PA). The cell line was subsequently stimulated every 2 wk using a final concentration of 104
line cells/ml, 10% rat Con A-stimulated supernatant, 20 I+g/ml rat MBP or 4 pM peptide,
and 2 x 106 ml SJL/J irradiated (3,300 rad) spleen cells in DME supplemented with 10%
FCS, 2 mM glutamine, 50 uM 2-ME, 100 U/ml penicillin, 100 Rg/ml streptomycin, and
1 mM pyruvate (DME growth media). T cell clones were derived by limiting dilutions at
0.4 cells per well and stimulated every 2 wk as described above.
T cell hybrids were produced by 50% PEG 1450 (J. T Baker Chemical Co., Phillipsburg,
NJ) fusion of equal numbers of a HGPRTdeficient BW5147 thymoma cell line and T cell
line stimulated for 24 h in 10% rat Con A supernatant. Hybridomas were selected with HAT
(100 pM hypoxanthine, 0.4 uM aminopterin, 16 pM thymidine), cloned twice at 0.4 cells
per well, and tested for antigen reactivity by the IL-2 assay.
Proliferation Assays.
￿
Antigen-primed LNC proliferation assays were set up by obtaining
10 d after immunization, draining LNC, and plating them at 4 x 105 per 200 Wl of Ventrex
HL-1 with and without antigen per well in 96-well microtiter plates. 4 d later, 1 ttCi
(3H]thymidine was added to each well. Cells were harvested 18 h later using a PHD cell har-
vester (Cambridge Technology, Inc., Cambridge, MA) and counts per minute were deter-
mined by a liquid scintillation counter. Samples were run in triplicate and the values are ex-
pressed as the cpm antigen minus cpm control.
Line and clone proliferation assays were performed using 105 line or clone cells, 4 x 105KONG ET AL .
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irradiated SJL/J spleen cells, and antigen in 200 gl Ventrex HL-1 medium per 200 pl in a
96-well microtiter plate. 2 d later 1 pCi [3Hlthymidine was added to each well and cells were
harvested 18 h later. Values are expressed as a stimulation index : cpm antigen/cpm control .
IL-2-release assay was done using HT-2 cells as described (17). Briefly, 105hybridoma cells,
5 x 10 5 PL/J irradiated spleen cells, and varying concentrations of antigen per 200 Al of
DME growth media were cultured in 96-well plates for 24-48 h . 50 pl of supernatant was
then transferred to 5 x 103 HT-2 cells in 50 pl ofDME growth media per well . After 24 h,
the proliferation was determined by pulsing each well with 1 pCi of [3Hlthymidine for 6 h .
Results
Selection ofPeptides.
￿
Previous studies have established that aCOOH-terminal peptic
fragment of rat, guinea pig, and bovine MBPs, each encompassing 81 amino acids,
contains the encephalitogenic epitope causingEAE in SJL/J mice (9) . Since the syn-
thetic peptide must most likely be homologous to mouse MBP in order to be en-
cephalitogenic, and since both small (14kD)and large (21 and 18.5kD)mouseMBPs
are known to contain the intact determinant (9), we first prepared two peptides selected
to encompass either side ofdeleted exonVI ofthe murine smallMBP gene, pM87-114
and pM155-168 (Fig. 1) . In this paper, synthetic murine MBP peptides are desig-
nated pM followed by the residue numbers . By this numbering system, exon VI
consists of residues 114-154, making pM87-114 and pMl55-168 contiguous sequences
of the murine smallMBP We included residue 114 on pM87-114, even though res-
idue 114 belongs to exonVI . Since residues 114 and 155 are both glycines, thisamino
acid is at the carboxy end ofpM87-114 in both the small and large forms ofMBP
(Fig . 1) . Subsequently, additional overlapping peptides were synthesized to delineate
the location of encephalitogenic epitopes in more detail .
Screening ofPeptides, pM87-114 andpM155-168 on anMBP-speck T Cell Line.
￿
Pep-
tides were initially screened for proliferation on an SJL/J, MBP-specific cell line,
SML-4 . Since an encephalitogenic synthetic peptide must stimulate aT cell response
in order to cause EAE, itwas expected that the potentially largenumber ofpeptides
needed to be screened for their encephalitogenic potential could be initially screened
for their ability to stimulate thisT cell line . In addition, this would allow us to find,
ifpresent,T cell epitopes that do not cause disease. TheT cell line used was derived
from an SJL/J mouse primed with whole rat MBP and was restimulated with this
same preparation ofMBP in vitro . This cell line, designated SML-4, was then used
to test both MBPsfrom various mammalian species and the synthetic peptides . Table
I shows that SML-4 reacted with MBP from all the species tested, including rat,
rabbit, porcine, guinea pig, and bovine . This broad pattern of reactivity is consis-
FIGURE 1 .
￿
Encephalitogenic synthetic peptides
ofsmall mouse MBP COOH-terminal fragment .
Peptideswere synthesized with the ABI 430A Pep-
tide Synthesizer and purified by semipreparative
HPLC . Peptides were tested for encephalitoge-
nicity by immunizing SJL/J mice with 20 nM
of peptide mixed with CFA supplemented with
H37Ra followed by 6 x 109 killedB . pertussis i.v.
24 and 72 h later . ( ") Location ofthe deleted exon
VI of the MBP gene. +, encephalitogenic; -,
nonencephalitogenic .
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TABLE I
Response of SML-4 T Cell Line to Xenogeneic MBP and
Synthetic Peptides, pM87-114 and pM155-168
105 SML-4 cells, 3 x 105 SJL/J irradiated spleen cells, and either 5 Wg MBP/ml
or 4 gM peptide were incubated in 200 ul ofVentrex HL-1 medium supplement-
ed with 2 mM glutamine per well for 3 d. 18 h before harvesting, 1 RCi of
[3H]thymidine was added to each well. Results are the mean value of triplicate
experiments. Additional 10-fold higher and lower concentrations ofantigens were
also tested and only the optimal values are shown on this table.
tentwith thenotion thatSML-4maybedirectedagainstthe highly conservedCOOH-
terminal region of small MBP When tested against the two synthetic peptides, the
SML-4 cell line reacted topM87-114, butwas totallyunreactiveto pM155-168 (Table
1). Thus, pM87-114 contains an MBP T cell determinant for SJL/J mice.
EAE Develops After Immunization withpM87-114 but not pM155-168.
￿
Mice were
immunized with the two peptides along with B. pertussis. Confirming the SML-4
proliferation findings, five of five mice developed EAE after immunization with
TABLE II
Incidence of EAE After Immunization with Synthetic Peptides
" Values are number ofaffected individuals per total tested. Each line represents
a separate immunization experiment.
1 Mean value of day of onset.
s Average maximal grade during first episode of EAE: 0 = normal, 1 = tail
paralysis, 2 - hindlimb weakness, 3 - hind and forelimb weakness, 4 = com-
plete paralysis of limb, and 5 = death.
II Location of the deleted exon VI of the MBP gene (see Table I).
Peptides
EAE
incidence"
Day of onsetl
(range)
Average
maximal
grades
pM87-114 5/5 10.8(9-14) 3.2
pM155-168 0/5
pM87-98 3/5 9.7 (9-10) 2.6
pM96-114 0/5
pM91-104 3/5 10.0 (10) 3.3
3/5 10.0(9-12) 2.3
pM107-11-162 0/5
PM88-98 2/5 10.3 (10-11) 3.0
2/5 10 .0 (10) 3.0
PM89-98 0/5
2/10 0.5
MBP cpm
Synthetic
peptides cpm
Control 1,907 Control 776
Rat 202,988 Rat MBP 45,719
Rabbit 213,579 pM87-114 11,741
Guinea pig 144,620 pM155-168 853
Bovine 190,281
Porcine 168,779pM87-114, but none of five after immunization with pM155-168 (Table II) . The
course ofEAE in pM87-114-immunized mice was relapsing or chronic neurologic
disease (Fig. 2, A-E). Consistent with previous reports, each relapse led to a greater
degree of residual neurologic impairment .
EAE-inducing Epitopes ResideBetween MurineMBP Residues 87-104.
￿
To furtherdefine
the encephalitogenicT cell epitope and to determine if other encephalitogenic epi-
topes are present within the COOH-terminal peptide of mouse MBP, additional
smaller and overlapping peptides were synthesized (Fig . 1) . The first of these pep-
tides synthesized and tested were pM87-98 and M96-114 . When tested against the
SML-4 cell line, only pM87-98 along with the parent molecules, pM87-114 and
whole MBP were recognized (Fig . 3) .
After several in vitro passages using rat MBP, theSML-4line became unreactive
to pM87-98 and all other peptides listed, although it was still highly reactive to rat
MBP . Therefore, peptides were screened for their ability to induce EAE by direct
immunization with peptide followed by intravenousB . pertussis . Table II shows that
two overlapping peptides, pM87-98 and pM91-104, induced severe EAE in SJL/J
mice . The disease was generally more severe with these peptides than with intact
ratMBP Peptide pM88-98 could also cause EAE, whereas pM89-98 elicited only
very mild acute disease in 2 of 10 mice (partial tail paralysis) . The disease course
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FIGURE 2 .
￿
Severity ofEAE after immunization
with synthetic COOH-terminalMBP peptides .
SJL/J mice were immunized at the base of the
tail withan emulsion containing 20nM ofeither
pM87-114 (A-E) or pM88-98 (F) with an equal
volume ofCFAsupplemented with H37Ra . 6 x
109 killedB . pertussu in 0.25ml saline were given
ix. 24 and 72 h later. Mice were observed daily
for EAE and graded on a five-point scale (see
Table I).
FIGURE 3 .
￿
Proliferative response of SML-4T cell line to rat MBP
and synthetic COOH-terminal peptides pM87-114,pM87-98, and
pM96-114 . See Table II for details ofproliferation assay . Results
are expressed as a stimulation index = cpmantigen/cpm control .
RatMBP(0), pM87-114 (O), pM87-98 (+), andpM96-114 (0).218
x 30
20
E
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wasagain similar to that after immunization with nativeMBP and varied from acute
to chronic relapsingdisease . Anexample ofa mouse showingaclassic relapsing dis-
ease after immunization with pM88-98 is shown in Fig . 2 F .
There are Likely at Least Two Epitopes within MBP Residues 87-104 that Can Induce
EAE. To distinguish whether pM87-98 and pM91-104 represented distinct epi-
topes within mouseMBP residues, 87-104, the SML-41ine, was subcultured by re-
stimulating with pM87-98 . Both this line and clones isolated from this line reacted
to pM87-98, but not to pM91-104 (Fig . 4) .
Some ofthepeptides appeared to be toxic to lines and clones at higher concentra-
tion . Since hybridomas were less sensitive to this effect, T cell hybridomas were de-
rivedfrom the pM87-98-stimulated SML-4line . The reactivity of thesehybridomas
to the peptides were similar to that found with the T cell clones (Fig . 5) .
Since it is possible that subculturing the line and clones may have resulted in the
selection ofa non-crossreactive epitope ofpM87-98, LNC proliferation after in vivo
pM87-98 priming wastested . Again, therewasreactivity against pM87-98, weaker
responses against thetruncatedpeptidespM88-98 and pM89-98, and no crossreac-
tivity to pM91-104 (Fig . 6) . Four additional encephalitogenicT cell lines, each de-
rived from a different mouse immunized with pM87-98, showed no crossreactivity
with pM91-104 (Table III) .
The reciprocal experiment of LNC proliferation to the various peptides after in
vivo priming with pM91-104 was also done (Fig . 7) . The LNC response was the
a
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FIGURE 4.
￿
Proliferative response of the SML-4T cell line
restimulated fortwo cycles with pM87-98 and a represen-
tativeT cellclone, 12#3, cloned from SML-4 usingpM87-98
as the antigen. Cells were tested with the two overlapping
encephalitogenic peptides, pM87-98 and 91-104 . The de-
tails of the proliferation assay are in Table II . Results are
expressed as a stimulation index = cpm antigen/cpm con-
trol . (A)SML-4T cell line and(B) SML-4-derived T cell
clone 12#3 . pM87-98 (+), pM91-104 (0), pM88-98 ("),
and pM89-98 (O) .
FIGURE 5 .
￿
HT-2 assay ofSML-4-derivedTcell hybrid 17 .1 specific
forpM87-98 . 105 hybrid 17 .1 cells and 5 x 105 irradiated SJL/J
spleen cells with varying concentration of antigen per 200 pl of
DME growth mediawere cultured for 48h . 50 pl ofsupernatant
was transferred to 5 x 103 HT-2 cells in 50 pl of growth media .
1 pCi of [3H]thymidine was added after 24 h and the cells were
harvested6h later. Thymidine uptake is expressed as : (cpm with
antigen) - (cpm with media alone). pM87-114 (0), pM87-98
(+), pM91-104 (O), pM88-98 (O) .KONO ET AL.
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FIGURE 6.
￿
ThepM87-98-primed LNCproliferative response to
encephalitogenic synthetic peptides. SJL/J mice were immunized
subcutaneously with an emulsion of equal volumes of 20 nM of
pM87-98 in PBS and CFA supplemented with killed H37Ra.
10 d later 4 x 105 draining LNC were added to varying concen-
trations of antigen in 200 gl of synthetic media, Ventrex HL-1.
4 d later, 1 gCi of [3H]thymidine was added and cells were har-
vested after 16 h. Thymidine uptake is expressed as: (cpm with
antigen) - (cpmwith mediaalone). pM87-98 (+), pM87-114(O),
pM91-104 (0), pM88-98 ("), pM89-98 (/). Results are repre-
sentative of three separate experiments.
greatest with pM91-104; however, pM87-98 had a good, although lower response.
The truncated peptides of pM87-98 could all elicit a response, except pM92-98,
which was completely nonstimulatory. These observations suggest that the major
response ofpM91-104 is directed to an epitope also containedwithin pM87-98, which
is likely the eight-residue peptide, pM91-98. The differences in magnitude may be
due in part to changes in reactivity due to the shorter lengths of these truncated
peptides. It is also possible that there are epitopes in pM91-104 that are not present
in pM87-98.
(SJL/J x PL/J)FI DevelopEAEtopM87-98.
￿
Since previous reportswere notclear
about whether (SJL/J x PL/J)Fi mice develop EAE to the COOH-terminal peptic
fragment of MBP (9, 10), we also tested (SJL/J x PL/J)Fi mice with one of the
encephalitogenic peptides, pM87-98. Two of four mice developed EAE with an av-
erage grade ofthree after immunization with this peptide. The day ofonset foreach
was 12 and 15 .
pM87-98Appears to be aMinor Epitope ofRat and Rabbit MBPfor SJLIJMice.
￿
We
observed that rat MBP-primed LNC had a much greater response to rat MBP than
rabbit MBP andsimilarly, rabbit MBP-primed LNC responded much more to rabbit
MBP(Fig. 8). Since the encephalitogenic determinant has the exact same sequence
in both rat and rabbit MBP, this implied that the xenogenic T cell epitope(s) was
much more immunodominant than the encephalitogenic Tcell epitope(s). In addi-
TABLE III
Response ofpM87-98-derived Encephalitogenic T Cell Lines to
M87-98 andpM91-104
See Table II for details ofproliferation assay conditions. Values are the mean
of triplicate experiments. T cell lines were tested for encephalitogenic poten-
tial by intravenous injection of 107 cells into SJL/J mice andfollowed for the
development of paralysis.
The final concentration of peptide used for the assay was 8 pM .
Lines cpm control cpm pM87-98' cpm pM91-104
SML-12.1 9,352 179,033 10,698
SML-12.3 1,442 59,380 1,883
SML-12.4 794 115,827 1,178
SML-12.5 812 58,155 340m
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FIGURE 7.
￿
ThepM91-104-primed LNC proliferative response to
encephalitogenic syntheticpeptides. The details ofthis procedure
are in thelegend to Fig. 5.Thymidineuptake is expressedas: (cpm
with antigen) - (cpm with mediaalone). pM87-98(+), pM91-104
(O), pM88-98(p), pM89-98("), pM90-98("), pM91-98(X),
pM92-98 (A). Results are representative of three separate ex-
periments.
tion, when mice primed with rat MBP were tested forrecall proliferation to several
peptides, the response of LNC to native MBP was much greater than to the en-
cephalitogenic peptides, pM87-114 and pM87-98, for which the response was not
significantly different than the control (Fig. 8). In contrast to this, when mice were
immunized with 50 nM of pM87-114, the LNC proliferative response was present
forpM87-114, pM87-98, andpM91-104, as well as thetruncated peptides ofpM87-98
(Fig. 9). There was also a good response with rat MBP (data not shown). Thus,
these peptide determinants appear to be minor epitopes of rat MBP
Discussion
In this study, we were able to identify in SJL/J mice two overlapping encephalito-
genic peptides within the COOH-terminal region of small mouse MBP by testing
for the ability of six overlapping synthetic peptides to induce EAE. Both of these
pathogenic peptides could elicit a Tcell response, whereas the other nonencephalito-
genic peptides in this region did not. To further characterize these peptides as dis-
tinct epitopes, we generated T cell lines to one peptide, pM87-98. These lines can
transfer EAE to naive mice, confirming that the disease is mediated by peptide an-
tigen-specific Tcells. The twopeptideantigens appeared to define separate epitopes,
since we could not demonstrate crossreactivity using lymph node cells primed in
vivo to pM87-98, and T cell lines, clones, and hybrids directed against pM87-98.
Thus, within a peptide determinant of 18 amino acids we are able to detect two
encephalitogenic T cell epitopes.
FIGURE 8.
￿
The rat (A) or rabbit (B) MBP-
primed LNC proliferative response to MBP
andencephalitogenic peptides. Thedetails of
this procedure are contained in thelegend of
Fig. 5. Thymidine uptake is expressed as:
(cpm with antigen) - (cpm with media
alone). Rat MBP (O), rabbit MBP (/),
pM87-114 ("), pM87-98 (0). Results are
representative ofthreeseparate experiments.KONG ET AL.
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FIGURE 9.
￿
ThepM89-114-primedLNCproliferative response to
encephalitogenic synthetic peptides. Thelegend ofFig. 5contains
the details forthe procedure. Thymidine uptake is expressed as:
(cpm with antigen) - (cpm with mediaalone). pM87-114 (0),
pM87-98 (O), pM91-104 (A), pM88-98 ("), pM89-98 (0),
pM90-98 (A), pM91-98 (+), pM92-98 (X). Results are repre-
sentative of three separate experiments.
SJL/J mice do not express the I-E& molecule due to a deletion of 650 by in the
promoter region (18, 19) and although intracytoplasmic I-Ea protein can be
identified, there does not appear to be any significant expression of the I-Ea pro-
tein on the cell surface (18). Both encephalitogenic peptides must therefore bind to
the I-As molecule. With the large region of overlapping amino acids, it is likely that
these two peptides share sequences that bind to the I-A' molecule, but have at least
two different sets of residues recognized by T cells. One set requires sequences be-
tween residues 87 and 90 for recognition and the other may recognize a number
of the shared residues between 91 and 98.
Severalwell-defined model systemsusingpanels ofcloned T cells have shown that
there are alimitednumber of peptide determinants that can account forthe murine
T cell response to anative proteinmolecule. Proteins studieshave included: cytochrome
c(20-22), lysozyme (23, 24), myoglobin (25-27), ovalbumin(28, 29), staphylococcal
nuclease (30), and theinfluenzavirus hemagglutinin (31). Forthe autoantigen, MBP,
a similarlimited number of peptide determinants are found since both SJL/J and
PL/J mice each develop EAE to a single, but different encephalitogenic peptide re-
gion. This limitednumber ofdeterminants mightbe especially expected in theSJL/J
strain because of both the deletion of approximately half of the T cell receptor Vp
gene segments (32) and the inability to express the I-E protein dimer (18, 19).
In contrast to the PL/J encephalitogenic peptide region, pM1-9NAc, which ap-
pears to have a single encephalitogenic T cell epitope (3), the SJL/J encephalito-
genic peptide region we have described here appears to have at least two distinct
encephalitogenic T cell epitopes. These observations are consistent with thecurrent
model of peptide-Ia binding based on the crystallographic structure of the class I
HLA-A2 (33, 34). Accordingto this model theSJL/Jencephalitogenic peptidewould
bind to the I-AS molecule lengthwise in a groove that is -20 amino acid residues
long. It is likely that the shared sequence between pM89-98 and 91-104 contains
the residues that bind to the I-A$ molecule and that the two T cell epitopes are the
result of Tcellsrecognizingdifferent sets ofamino acidswithin MBP residues 89-104.
Further mappingof T cell reactivity within this region may uncover additional epi-
topes. Careful mapping of peptide determinants forother nonautoantigens such as
lysozyme (35), cytochrome c (36), myoglobin (37), and ovalbumin (38) have shown
a similar heterogeneity of T cell epitopes for a peptide determinant. The apparent
single encephalitogenic T cell epitope, pMl-9Ac found in the PL/J mice (3) may22 2
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be explained by its position at the NH2-terminal of MBP and the use of rat MBP
as the immunogen. Based on themodelof peptide determinants fornonautoantigens
(35-38), multiple T cell epitopes would be expected along an la-binding peptide
region. Since murine MBP differs from rat MBP at residues 10 and 11, due to a
deletion of histidine and glycine in murine MBP, immunization of PL/J mice with
rat MBP will producemurine MBP-specific Tcellsrestricted to reactivity to pM1-9Ac.
As expected, immunization with rat MBP yields additional T cell epitopes, involving
residues 10 and 11 of rat MBP, which are nonencephalitogenic most likely because
they fail to recognize murine MBP (10). Immunization of PL/J mice with alonger
NH2-terminal peptide homologous to mouse MBP may uncover additional en-
cephalitogenic epitopes, involving residues 10 and 11 of murine MBP Although
pM1-9Ac appears to be short enough to define a single epitope, fine mapping of
pM1-9Ac by amino acid substitutions may reveal more epitope(s). The presence
of multiple T cell epitopes may possibly play a role in relapsingdisease. Additional
truncated and single aminoacid substituted peptides will allowus to map and assess
the significance of these encephalitogenic epitopes in greater detail.
One of the peptides, pM87-98, was tested on (SJL/J x PL/J)Fi mice and found
to be highly encephalitogenic. Although only asmall number of mice were studied,
the incidence and severity of disease were similar to that induced in the SJL/J pa-
rental strain. Prior studies using peptic fragments of guinea pig MBP showed that
these (SJL/J x PL/J)Fi mice developed EAE with an incidenceof 11/14 peptide frag-
ment residues 1-37, but only 1/14 to residues 89-169 (9). In addition, MBP-specific
encephalitogenic T cell clones derived from (SJL/J x PL/J)Fi mice have all been
reactive with the NH2-terminal epitope, but not with the COOH-terminal peptide
(39). The resultsof studiesusingpreparations of COOH-terminal peptide fragments
may have been affected by contamination with small amounts of NH2-terminal pep-
tides, and therefore, it was unclear whether the COOH-terminal peptide could in-
duce any EAE in (SJL/J x PL/J)Fi mice (10). Since we have found that (SJL/J x
PL/J)Fi mice develop EAE to the synthetic peptide pM87-98, it is unlikely that
depletion of the T cell repertoire due to thymic selection (40) is the cause of the
bias toward recognition of the NH2-terminal peptide. It would appear from lymph
node proliferation studies that antigen processing of MBP may be the major deter-
minant of this bias (Kono, D., unpublished data).
This (SJL/J x PL/J)Fi bias toward recognition of the NH2-terminal peptide is
consistent with our finding of the SJL/J MBP COOH-terminal peptides as being
a minor or "subdominant" (41) determinant compared with the PL/J MBP NH2-
terminal peptide which is "immunodominant" (Kono, D., unpublished data). In ad-
dition, the observation that xenogeneic MBP T cell epitopes appear to be im-
munodominant may account for the difficulty in obtainingencephalitogenic T cell
clones in SJL/J mice after immunization with xenogeneic MBP (14, 42, 43), and
the success of obtaining encephalitogenic T cell clones by alternating MBP from
different species to restimulate Tcell linesbefore cloning(4). AlternatingMBPfrom
different species would select for T cells recognizing MBP determinants common
to the different species that would also be homologous to mouse MBP The fact that
a minor peptide determinant can cause EAE raises the question of whether addi-
tional encephalitogenic minorpeptide determinants of MBP are present that have
escaped detection. To addressthis question, overlappingpeptides encompassing theKONO ET AL.
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whole MBP protein will likely have to be synthesized and characterized for their
ability to solicit T cell responses and EAE. In addition, neonatal tolerance to syn-
thetic peptides has been shown to be an effective method for tolerizing mice to a
single specific epitope(44). This approach may prove useful for determiningwhether
there are other encephalitogenic MBP-specific epitopes in SJL/J and PL/J mice.
In future studies we plan to use murine MBP in order to avoid the bias in T cell
repertoire caused by the immunodominant xenogenic T cell epitopes of rat MBP.
DeLisi and Berzofsky (45) have found that the majority of immunodominant T
cell peptide epitopes tend to form amphipathic a-helical structures with periodical
variations in theirhydrophobicity so that hydrophobicresidues areprimarilyon one
side of the a helix and hydrophilic residues on the other. Based on this model, an
algorithm wassubsequently createdthat was able to identify 75% ofaseries ofknown
T cell epitopes (46). When we applied this algorithm to the small mouse COOH
terminal of MBP, the only region with sufficient amphipathic properties to score
as immunodominant was one spanning MBP, residues 83-93. Both oftheencephalito-
genic peptides contain residues within this .region. These data suggest that the am-
phipathic model of peptides capable of activating T cells may be helpful in iden-
tifying potential T cell determinants but it certainlydoes not predict theirlocations
precisely.
The observations on theencephalitogenic determinants ofMBP for both the SJL/J
and PL/J mice show that the response to this autoantigen from a "privileged site"
follows the same principles forT helper cell antigen recognition as any nonautoan-
tigen. This maydiffer from autoantigens that are accessible to thethymus, in which
there maybe deletion ofTcells recognizingthese antigens. This suggests that inter-
ventions that suppress the T cell response to nonautoantigens may also be successful
in suppressing the T cell response to autoantigens from privileged sites and may
play a role in therapy since the T helper cell is of major importance in the pathogen-
esis of autoimmune disease.
T helper cells alone can transfer disease in several models of autoimmunity such
as EAE (1-4), adjuvant arthritis (8), experimental allergic thyroiditis (6), and col-
lagen arthritis (47). In addition, treatmentof animals with anti-L3T4has been suc-
cessfulin treating EAE(48), experimental allergic thyroiditis (6), murine lupus(5),
and collagen arthritis (7). EAE is the prototype model of antigen-specific T helper
cell-mediated autoimmune disease since it is the best characterized and the neuro-
logicaldamage seen in this diseasemaybe directly mediated by Thelper cells alone.
Thus, principles derived from this modelmay have direct implications for the other
animal models and human autoimmune diseases. Since theMHC-peptide epitopeT
cell receptor complex interaction is one of the few pathogenic mechanisms with
specificity, specific intervention directed at this complexmaylead to specific therapy
ofautoimmune disease without suppressionofthe whole immune system. The finding
now of a limited number of encephalitogenic T cell peptide determinants to MBP
in two different strains of mice supports this possibility. Possibly antibodies directed
against clonotypic determinants or even variable gene segments oftheTcell receptor
may provide specific treatment for EAE, since there appears to be a very limited
variable gene segment usage for a single T cell epitope (49, 50). In fact, we have
recently discovered a highly restricted use of variable gene segments in both the a
and 0 chains of the T cell receptors recognizing the PL/J encephalitogenic epitope224
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(Urban, J., manuscript in preparation). However, our findings ofat least two en-
cephalitogenic T cell epitopes within a given peptide determinant and that minor
or subdominant determinants are also encephalitogenic point to the complexity of
the interactions and the potential difficulties that must be addressedwhen devising
strategies toward specifictherapydirected at the MHC-peptide epitopeTcellreceptor
interaction. Further studies to define and map the encephalitogenic T cell epitopes
for murine MBP using synthetic peptides will provide a better understanding of
how this interaction contributes to the development of autoimmunity.
Summary
Experimental allergic encephalomyelitis (EAE) is an autoimmune demyelinating
disease ofthecentral nervous system (CNS) thatoccurs afterimmunization ofanimals
with myelin basic protein (MBP). The disease is a prototype model for the study
ofantigen-specificThelper cell-mediated autoimmunedisease. InSJL/J mice, EAE
is mediated by T helper cells directed against a 40-amino acid COOH-terminal
peptic fragment of mouse small MBP To identify the minimal T cell epitopes of
MBP responsible for EAE, overlapping peptides completely encompassing the epi-
topes within thisregion were synthesized. A28-residue peptide ofmouse MBP span-
ning residues 87-114 (pM87-114) was able toelicit both a strong T cell response and
chronicrelapsingdisease. To better localize the T cell epitopes, shorterpeptides within
thisregion were synthesized and two overlappingpeptides, pM87-98 and pM91-104,
were able to induce EAE. T cell clones and bulk lymph node cell populations reac-
tive with pM87-98 did not respond to pM91-104. However, lymph node cells reac-
tive with pM91-104 also reacted with pM87-98, thus showing that these two pep-
tides represent contiguous, butdistinct encephalitogenic epitopes andthatboth these
epitopes may becontained within pM87-98. In addition, pM87-114 and pM87-98
were found to be minor determinants ofthe total T cell response to rat and rabbit
MBP The restricted response to MBP in SJL/J mice is similar to that ofthe PL/J
mice in that each appears to have only a single peptide region in MBP that elicits
encephalitogenic Tcells. However, within the region studied, there were two ifnot
more T cell epitopes. This differs from the single encephalitogenic PL/J epitope.
These findings ofa single encephalitogenic peptide region with multiple T cell epi-
topes and the fact that encephalitogenic T cell epitopes may be subdominant have
implicationsforthe design oftreatmentsdirectedat the Tcell receptor-MHC-peptide
epitope complex in autoimmune disease.
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script.
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